Comparative Pharmacology
Head-to-head clinical analysis: ACTEMRA versus KEVZARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTEMRA versus KEVZARA.
ACTEMRA vs KEVZARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTEMRA (tocilizumab) is a recombinant humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling. This blocks the pro-inflammatory effects of IL-6, including T-cell activation, B-cell differentiation, acute phase protein synthesis, and macrophage activation.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
4 mg/kg IV every 4 weeks initially, then increase to 8 mg/kg IV every 4 weeks based on clinical response (max 800 mg per dose). Alternatively, 162 mg SC every week or every other week for moderate to severe RA. For giant cell arteritis: 162 mg SC every week plus tapering corticosteroids.
200 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 13 days (range 11–17 days) for intravenous dosing and 8–10 days for subcutaneous dosing, due to concentration-dependent clearance and target-mediated elimination. Clinical context: The long half-life supports every-4-week dosing in stable patients.
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Primarily via the reticuloendothelial system and target-mediated clearance; renal excretion is negligible (<10% as unchanged drug in urine). Biliary/fecal excretion is not a major route; however, after intravenous administration, approximately 80% of the dose is recovered in feces as metabolites over 4 weeks, with <1% as parent drug. The remainder is catabolized to amino acids.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Category C
Category C
IL-6 Receptor Antagonist
Monoclonal Antibody, IL-6 Receptor Antagonist